| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.04. | Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why | 12 | Benzinga.com | ||
| 24.04. | Eisai and BioArctic sign research evaluation agreement for potential new Alzheimer's treatment | 7 | PMLiVE | ||
| 22.04. | Eisai hunts for next Alzheimer's drug with new research pact | 3 | BioPharma Dive | ||
| 22.04. | BioArctic, Eisai Ink Research Agreement for BAN2802 in AD | 2 | Contract Pharma | ||
| 22.04. | BioArctic partners with Eisai on Alzheimer's treatment | 4 | Pharmaceutical Technology | ||
| 21.04. | BioArctic And Eisai Collaborate On Evaluating BAN2802 For Alzheimer's Disease | 4 | RTTNews | ||
| 20.04. | BioArctic and Eisai sign research evaluation agreement regarding BAN2802 | 502 | PR Newswire | STOCKHOLM, April 20, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic AB and Eisai Co., Ltd., have entered into a research evaluation agreement... ► Artikel lesen | |
| 18.04. | Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) | 352 | JCN Newswire | As a Part of FY2024 Commendation For Science and Technology by MEXTTOKYO, Apr 18, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Based... ► Artikel lesen | |
| 17.04. | Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan | 213 | JCN Newswire | Addressing Medical Needs for Patients Who Cannot Take the Medication OrallyTOKYO, Apr 17, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered... ► Artikel lesen | |
| 12.04. | Eisai on your hi-fi: Leqembi maker supports creation of Alzheimer's podcast miniseries | 315 | FiercePharma | ||
| 03.04. | French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics | 303 | JCN Newswire | TOKYO, Apr 3, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the French Overseas Territories... ► Artikel lesen | |
| 02.04. | Eisai to divest rights for two therapies to Kaken | 4 | Pharmaceutical Technology | ||
| 01.04. | COGSTATE LTD: Eisai and Cogstate Amend Global License Agreement | - | ASX | ||
| 01.04. | Eisai and Biogen move to bring IV maintenance dosing for Leqembi to the US | 13 | Pharmaceutical Technology | ||
| 01.04. | Eisai, Biogen's injectable Leqembi delayed as FDA asks for more data | 7 | FiercePharma | ||
| 01.04. | Eisai submits sBLA for monthly maintenance dose of Alzheimer's drug Leqembi | 4 | Seeking Alpha | ||
| 01.04. | Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA | 592 | JCN Newswire | TOKYO and CAMBRIDGE, Mass., Apr 1, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Eisai submitted to the U.S. Food andDrug Administration (FDA) a Supplemental Biologics... ► Artikel lesen | |
| 01.04. | Eisai Submits Leqembi SBLA For IV Maintenance Dosing In Early Alzheimer's Disease | 611 | AFX News | WESTON (dpa-AFX) - Eisai submitted to the U.S. Food and Drug Administration a Supplemental Biologics License Application or sBLA for monthly lecanemab-irmb (U.S. brand name: Leqembi) intravenous... ► Artikel lesen | |
| 29.03. | Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical | 287 | JCN Newswire | TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic... ► Artikel lesen | |
| 29.03. | Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture | 264 | JCN Newswire | TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that "NouKNOW", Eisai's self-check tool for brain health, was certified as a "ME-BYO BRAND" by Kanagawa prefecture.About "ME-BYO... ► Artikel lesen |
Seite:
1 2 3 4 5 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 4.633 |
| NEL | 3.587 |
| PALANTIR TECHNOLOGIES | 3.504 |
| TUI | 2.687 |
| BAYER | 2.480 |
| NVIDIA | 2.351 |
| DEUTSCHE BANK | 2.067 |
| INFINEON | 1.962 |
| BYD | 1.889 |
| SUPER MICRO COMPUTER | 1.826 |
| BIONTECH | 1.795 |
| MERCEDES-BENZ | 1.760 |
| RHEINMETALL | 1.687 |
| DEUTSCHE LUFTHANSA | 1.628 |
| PLUG POWER | 1.576 |
| RWE | 1.470 |
| VARTA | 1.439 |
| AIXTRON SE | 1.434 |
| TESLA | 1.428 |
| RENK GROUP | 1.385 |
| COMMERZBANK | 1.332 |
| SIEMENS ENERGY | 1.266 |
| VOLKSWAGEN | 1.245 |
| ALLIANZ | 1.239 |
| BASF | 1.214 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
